-+ 0.00%
-+ 0.00%
-+ 0.00%

CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCES SARAH CANNON RESEARCH INSTITUTE AT COLORADO BLOOD CANCER INSTITUTE AS KEY CLINICAL TRIAL SITE FOR ITS PHASE 1 CLINICAL TRIAL OF CER-1236 IN ACUTE MYELOID LEUKEMIA

Reuters·04/24/2025 12:15:00

Please log in to view news